Robust, GMP-compliant quantitative assay procedures are critical for quality control in pharmaceutical manufacturing. This whitepaper explores the advantages of using quantitative Nuclear Magnetic Resonance (qNMR) with the Fourier 80 benchtop spectrometer for analyzing fluorinated active pharmaceutical ingredients.
Image Credit: smereka/Shutterstock.com
Thanks to its multinuclear capabilities, the Fourier 80 supports straightforward implementation of 19F NMR quantitative assays - fully aligned with regulatory expectations.
The high specificity of 19F NMR simplifies procedure development and enables reliable quantification even in complex formulations, such as finished drug products. This approach streamlines both design and execution, making it a practical solution for modern QC environments.
Download the full whitepaper here.
About Bruker BioSpin Division
The Bruker BioSpin Division designs, manufactures, and distributes advanced scientific instruments based on magnetic resonance, preclinical imaging technologies, and biosensor technologies. These include our industry-leading NMR and EPR spectrometers, imaging systems utilizing MRI, PET, SPECT, CT, Optical and MPI modalities, as well as molecular interaction technologies like SPR, switchSENSE® and single-cell Interaction Cytometry (scIC). The Division also offers integrated software solutions and automation tools to support digital transformation across research and quality control environments.
Our customers in academic, government, industrial, and pharmaceutical sectors rely on these technologies to gain detailed insights into molecular structure, dynamics, and interactions. Our solutions play a key role in structural biology, drug discovery, disease research, metabolomics, and advanced materials analysis. Recent investments in lab automation, optical imaging, and contract research services further strengthen our ability to support evolving customer needs and enable scientific innovation.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.